Program
elismetrep
Also written as “MT-8554”, “Elismetrep” and “MT-8554 low dose”.
Its studies are mostly in Migraine Disorders · Hot Flashes, led by 2 companies.
Drug pageElismetrep: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tanabe Pharmaits history only | 100 open or running | phase 2since May 29, 2017 | Apr 16, 2015 | none ahead |
| TriGemX Bio | 43 open or running | phase 3since Jun 9, 2026 | Feb 21, 2025 | Feb 2027phase 3 · NCT07645924 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of TriGemX Bio only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2017Named elismetrepINNProposed as its International Nonproprietary Name in WHO's List 118 · before, MT-8554
- Feb 21, 2025First study: phase 2 study in Migraine DisordersFirst studyNCT06848075 · 431 enrolled · United States
- Jun 9, 20262 phase 3 studiesPhase 3 reachedNCT07645924, NCT07674654
- Sep 7, 2026Phase 3 study in Migraine DisordersNCT07816367 · 1,500 planned · United States
Ahead
- Feb 2027Primary completion: phase 3 study in Migraine DisordersNCT07645924
- Oct 2027Primary completion: phase 3 study in Migraine DisordersNCT07816367
- Jun 2028Primary completion: phase 3 study in Acute MigraineNCT07674654
TargetBeta
“Transient receptor potential cation channel subfamily M member 8 inhibitor”ChEMBL 37, by rule
Studies
All 4 TriGemX Bio leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07816367Migraine Disorders · United States | 3 | Recruiting | Oct 2027 | 1,500 |
| NCT07674654Acute Migraine · United States | 3 | Recruiting | Jun 2028 | 1,000 |
| NCT07645924Migraine Disorders · United States | 3 | Recruiting | Feb 2027 | 1,800 |
| NCT06848075Migraine Disorders · United States | 2 | Completed | Aug 4, 2025 | 431 |
How it is read
Names in the registry
- “MT-8554”, 4 entries
- “Elismetrep”, 3 entries
- “MT-8554 low dose”, 3 entries
- “MT-8554 high dose”, 3 entries
- “MT-8554 middle dose”, 2 entries
Conditions, from the studies’ own filings
- Migraine Disorders, 4 studies
- Hot Flashes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.